Restoration of natural killer activity in hepatocellular carcinoma by treatment with antibody against granulin-epithelin precursor

References

• Levy EM, Roberti MP, Mordoh J. Natural killer cells in human cancer: from biological functions to clinical applications. J Biomed Biotechnol 2011; 2011:676198; PMID:21541191; http://dx.doi.org/10.1155/2011/676198
   PubMed Web of Science ®Google Scholar
• Caligiuri MA. Human natural killer cells. Blood 2008; 112:461-9; PMID:18650461; http://dx.doi.org/10.1182/blood-2007-09-077438
   PubMed Web of Science ®Google Scholar
• Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000; 356:1795-9; PMID:11117911; http://dx.doi.org/10.1016/S0140-6736(00)03231-1
   PubMed Web of Science ®Google Scholar
• Eckl J, Buchner A, Prinz PU, Riesenberg R, Siegert SI, Kammerer R, Nelson PJ, Noessner E. Transcript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging. J Mol Med (Berl) 2011; 90:55-66; PMID:21870102; http://dx.doi.org/10.1007/s00109-011-0806-7
   PubMedGoogle Scholar
• Halama N, Braun M, Kahlert C, Spille A, Quack C, Rahbari N, Koch M, Weitz J, Kloor M, Zoernig I, et al. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res 2011; 17:678-89; PMID:21325295; http://dx.doi.org/10.1158/1078-0432.CCR-10-2173
   PubMed Web of Science ®Google Scholar
• Chew V, Chen J, Lee D, Loh E, Lee J, Lim KH, Weber A, Slankamenac K, Poon RT, Yang H, et al. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut 2012; 61:427-38; PMID:21930732; http://dx.doi.org/10.1136/gutjnl-2011-300509
   PubMed Web of Science ®Google Scholar
• Taketomi A, Shimada M, Shirabe K, Kajiyama K, Gion T, Sugimachi K. Natural killer cell activity in patients with hepatocellular carcinoma: a new prognostic indicator after hepatectomy. Cancer 1998; 83:58-63; PMID:9655293; http://dx.doi.org/10.1002/(SICI)1097-0142(19980701)83:1<58::AID-CNCR8>3.0.CO;2-A
   PubMed Web of Science ®Google Scholar
• Chew V, Tow C, Teo M, Wong HL, Chan J, Gehring A, Loh M, Bolze A, Quek R, Lee VK, et al. Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol 2010; 52:370-9; PMID:19720422; http://dx.doi.org/10.1016/j.jhep.2009.07.013
   PubMed Web of Science ®Google Scholar
• Zerbini A, Pilli M, Laccabue D, Pelosi G, Molinari A, Negri E, Cerioni S, Fagnoni F, Soliani P, Ferrari C, et al. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology 2010; 138:1931-42; PMID:20060829; http://dx.doi.org/10.1053/j.gastro.2009.12.051
   PubMed Web of Science ®Google Scholar
• Jinushi M, Takehara T, Tatsumi T, Hiramatsu N, Sakamori R, Yamaguchi S, Hayashi N. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol 2005; 43:1013-20; PMID:16168521; http://dx.doi.org/10.1016/j.jhep.2005.05.026
   PubMed Web of Science ®Google Scholar
• Cai L, Zhang Z, Zhou L, Wang H, Fu J, Zhang S, Shi M, Zhang H, Yang Y, Wu H, et al. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol 2008; 129:428-37; PMID:18824414; http://dx.doi.org/10.1016/j.clim.2008.08.012
   PubMed Web of Science ®Google Scholar
• Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, Lehner F, Manns MP, Greten TF, Korangy F. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 2009; 50:799-807; PMID:19551844; http://dx.doi.org/10.1002/hep.23054
   PubMed Web of Science ®Google Scholar
• Bateman A, Bennett HP. The granulin gene family: from cancer to dementia. Bioessays 2009; 31:1245-54; PMID:19795409; http://dx.doi.org/10.1002/bies.200900086
   PubMed Web of Science ®Google Scholar
• Cheung ST, Cheung PF, Cheng KC, Wong NC, Fan ST. Granulin-epithelin precursor and ATP-dependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance. Gastroenterology 2011; 140:344-55; PMID:20682318; http://dx.doi.org/10.1053/j.gastro.2010.07.049
   PubMedGoogle Scholar
• Cheung ST, Wong SY, Lee YT, Fan ST. GEP associates with wild-type p53 in hepatocellular carcinoma. Oncol Rep 2006; 15:1507-11; PMID:16685387
   PubMedGoogle Scholar
• Cheung ST, Wong SY, Leung KL, Chen X, So S, Ng IO, Fan ST. Granulin-epithelin precursor overexpression promotes growth and invasion of hepatocellular carcinoma. Clin Cancer Res 2004; 10:7629-36; PMID:15569995; http://dx.doi.org/10.1158/1078-0432.CCR-04-0960
   PubMed Web of Science ®Google Scholar
• Yip CW, Cheung PF, Leung IC, Wong NC, Cheng CK, Fan ST, Cheung ST. Granulin-epithelin precursor interacts with heparan sulfate on liver cancer cells. Carcinogenesis 2014; 35:2485-94; PMID:25115442; http://dx.doi.org/10.1093/carcin/bgu164
   PubMedGoogle Scholar
• Ho JC, Ip YC, Cheung ST, Lee YT, Chan KF, Wong SY, Fan ST. Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma. Hepatology 2008; 47:1524-32; PMID:18393387; http://dx.doi.org/10.1002/hep.22191
   PubMed Web of Science ®Google Scholar
• Wong NC, Cheung PF, Yip CW, Chan KF, Ng IO, Fan ST, Cheung ST. Antibody against granulin-epithelin precursor sensitizes hepatocellular carcinoma to chemotherapeutic agents. Mol Cancer Ther 2014; 13:3001-12; PMID:25253787; http://dx.doi.org/10.1158/1535-7163.MCT-14-0012
   PubMedGoogle Scholar
• Cheung PF, Cheng CK, Wong NC, Ho JC, Yip CW, Lui VC, Cheung AN, Fan ST, Cheung ST. Granulin-epithelin precursor is an oncofetal protein defining hepatic cancer stem cells. PLoS One 2011; 6:e28246; PMID:22194816; http://dx.doi.org/10.1371/journal.pone.0028246
   PubMedGoogle Scholar
• Cheung PF, Yip CW, Wong NC, Fong DY, Ng LW, Wan AM, Wong CK, Cheung TT, Ng IO, Poon RT, et al. Granulin-epithelin precursor renders hepatocellular carcinoma cells resistant to natural killer cytotoxicity. Cancer Immunol Res 2014; 2:1209-19; PMID:25315249; http://dx.doi.org/10.1158/2326-6066.CIR-14-0096
   PubMed Web of Science ®Google Scholar
• Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22:633-40; PMID:11698225; http://dx.doi.org/10.1016/S1471-4906(01)02060-9
   PubMed Web of Science ®Google Scholar
• Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001; 97:3146-51; PMID:11342442; http://dx.doi.org/10.1182/blood.V97.10.3146
   PubMed Web of Science ®Google Scholar
• Hayakawa Y, Kelly JM, Westwood JA, Darcy PK, Diefenbach A, Raulet D, Smyth MJ. Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J Immunol 2002; 169:5377-81; PMID:12421908; http://dx.doi.org/10.4049/jimmunol.169.10.5377
   PubMed Web of Science ®Google Scholar
• Kamimura H, Yamagiwa S, Tsuchiya A, Takamura M, Matsuda Y, Ohkoshi S, Inoue M, Wakai T, Shirai Y, Nomoto M, et al. Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence. J Hepatol 2012; 56:381-8; PMID:21756848; http://dx.doi.org/10.1016/j.jhep.2011.06.017
   PubMed Web of Science ®Google Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012; 12:278-87; PMID:22437872; http://dx.doi.org/10.1038/nrc3236
   PubMed Web of Science ®Google Scholar
• Moretta L, Bottino C, Pende D, Castriconi R, Mingari MC, Moretta A. Surface NK receptors and their ligands on tumor cells. Semin Immunol 2006; 18:151-8; PMID:16730454; http://dx.doi.org/10.1016/j.smim.2006.03.002
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Swann J, Cretney E, Zerafa N, Yokoyama WM, Hayakawa Y. NKG2D function protects the host from tumor initiation. J Exp Med 2005; 202:583-8; PMID:16129707; http://dx.doi.org/10.1084/jem.20050994
   PubMed Web of Science ®Google Scholar
• Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, Knoblaugh S, Cado D, Greenberg NM, Raulet DH. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008; 28:571-80; PMID:18394936; http://dx.doi.org/10.1016/j.immuni.2008.02.016
   PubMed Web of Science ®Google Scholar
• Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 2004; 48:411-24; PMID:15349816; http://dx.doi.org/10.1387/ijdb.041811af
   PubMed Web of Science ®Google Scholar
• Hogarth PM, Pietersz GA. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Disc 2012; 11:311-U87; PMID:22460124; http://dx.doi.org/10.1038/nrd2909
   PubMed Web of Science ®Google Scholar
• Guo CL, Yang HC, Yang XH, Cheng W, Dong TX, Zhu WJ, Xu Z, Zhao L. Associations between infiltrating lymphocyte subsets and hepatocellular carcinoma. Asian Pac J Cancer Prev: APJCP 2012; 13:5909-13; PMID:23317279; http://dx.doi.org/10.7314/APJCP.2012.13.11.5909
   PubMedGoogle Scholar
• Maghazachi AA. Role of chemokines in the biology of natural killer cells. Curr Topics Microbiol Immunol 2010; 341:37-58; PMID:20369317
   PubMed Web of Science ®Google Scholar
• Chow MT, Luster AD. Chemokines in Cancer. Cancer Immunol Res 2014; 2:1125-31; PMID:25480554; http://dx.doi.org/10.1158/2326-6066.CIR-14-0160
   PubMed Web of Science ®Google Scholar
• Koizumi K, Hojo S, Akashi T, Yasumoto K, Saiki I. Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci 2007; 98:1652-8; PMID:17894551; http://dx.doi.org/10.1111/j.1349-7006.2007.00606.x
   PubMed Web of Science ®Google Scholar
• Kohga K, Takehara T, Tatsumi T, Ishida H, Miyagi T, Hosui A, Hayashi N. Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9. Hepatology 2010; 51:1264-73; PMID:20099300; http://dx.doi.org/10.1002/hep.23456
   PubMed Web of Science ®Google Scholar
• Sprinzl MF, Reisinger F, Puschnik A, Ringelhan M, Ackermann K, Hartmann D, Schiemann M, Weinmann A, Galle PR, Schuchmann M, et al. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. Hepatology 2013; 57:2358-68; PMID:23424039; http://dx.doi.org/10.1002/hep.26328
   PubMed Web of Science ®Google Scholar